Agosto 2021 - Nouscom

Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer

BASEL, Switzerland – August 24th, 2021: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced that the first [...]

Nouscom highlights innovative science behind VENUS, its novel algorithm for identifying and prioritizing patient-specific tumor neoantigens for personalized cancer immunotherapy

VENUS (Vaccine-Encoded Neoantigens Unrestricted Selection) is Nouscom’s proprietary algorithm designed to enhance the predictive accuracy of personalized neoantigen selections that may induce an [...]

error: Content is protected !!!